In Chronic Myeloid Leukemia (CML), standard treatment consists of modern tyrosine-kinase inhibitors (TKI). Nevertheless, there is evidence that immune responses against leukemiaassociated antigens (LAA) may play an important role in disease control. Dendritic cell (DC)-based immunotherapy is able to induce T cell responses against LAA and might therefore pose an interesting therapeutic option in CML, especially in the setting of minimal residual disease (MRD). GMP production of DC for clinical vaccination remains a time-and costintensive procedure and standardized DC generation is warranted. We asked whether maturation-induction with IFN-γ and IFN-α has an influence on functional properties of DC derived from peripheral blood mononuclear cells (PBMC) in CML patients. Monocyte-derived DC from healthy donors and from patients with CML were analyzed after maturationinduction with our TNF-α-containing standard cytokine cocktail with or without addition of IFN-α and/or IFN-γ. Our results confirm that the addition of IFN-γ leads to enhanced IL-12 secretion in healthy donors. In contrast, in CML patients, IFN-γ was not able to increase IL-12 secretion, possibly due to a higher degree of cell adherence and lower cell yield during the cell culture. Our data suggest, that-in contrast to healthy donors-, additional interferons are not beneficial for maturation induction during large-scale DC production in patients with CML.
Introduction
Chronic myeloid leukemia is a clonal myeloproliferative disorder in which the characteristic reciprocal translocation, t(9;22)(q34;q11) forms the Philadelphia chromosome and leads to the fusion gene BCR-ABL. 1 In CML, the predominant gene product of this reciprocal translocation is the BCR/ABL fusion protein p210, which shows abnormal tyrosine-kinase activity that is crucial for the pathogenesis of the disease. 2, 3 The introduction of tyrosine kinase inhibitors (TKI) has revolutionized CML treatment and has become a paradigm of "targeted therapy" since the late 1990ies. 4, 5 TKI treatment with Imatinib and in particular the second generation TKI Nilotinib and Dasatinib has substantially increased the proportion of patients achieving deep molecular responses. This improvement of the quality of remission has translated into a substantially longer progression-free and promising overall survival. 5 However, most CML patients-despite achieving deep molecular remissions-remain BCR/ABL-positive, suggesting disease persistence at least at a very low level. In this situation of minimal residual disease (MRD) on a molecular level, additional immunotherapeutic strategies such as interferon therapy or vaccination against leukemiaassociated antigens seems particularly promising with regard to a possible eradication of residual leukemia cells. In fact, there is a large body of evidence showing that CML is an "immunoresponsive" disease: 1) interferon therapy is able to induce complete cytogenetic responses in up to 30% of CML patients; 6 2) induction of T cell responses against proteinase-3 correlates with ongoing remissions under interferon therapy and after allogeneic stem cell transplantation (SCT); 7 3) donor lymphocyte infusions (DLI) are able to induce long-lasting remissions in relapsed CML patients after allogeneic SCT 8 [20] [21] [22] [23] [24] Therefore, the deep molecular responses observed under TKI therapy may also reverse immunosuppression that is induced by a large tumor burden. DC are key regulators of MHC-restricted T cell responses in humans and are considered as "nature´s adjuvant". 25 The feasibility of DC-based immunization strategies in CML patients has been demonstrated by several groups including ours, although most of these studies were performed in CML patients, who had not achieved a major molecular remission. 15, [26] [27] [28] [29] Ex-vivo generation and maturation of DC is a crucial step for these strategies and different cytokine cocktails have been described which are mainly based on GM-CSF, IL-4 and TNF- 33, 34 Therefore, the aim of our present study was to assess the influence of interferons during ex vivo DC generation on the functional properties of DC in CML patients. 
Discussion
IL-12 secretion by DC is a very helpful surrogate parameter for the TH1-polarizing capacity of in vitro generated DC. 35 Previous reports in healthy individuals have described multiple different cytokine cocktails for maturation induction in DC. IL-12 production was commonly used as a measure for the TH1-polarizing capacity. IL-1ß/TNF-α and IFN-γ are amongst the cytokines which have been used for ex vivo DC generation. 33, 36 Subsequently, it was demonstrated that combined use of IFN-γ and IFN-α was able to induce a mature DC phenotype with superior IL-12 production in DC from healthy individuals. 34, 37 During the interaction of DC with T cells, CD40-ligation is a crucial step leading to IL-12 production and consequently TH1-polarized T cells. 35, 38 Additionally, it has recently been shown, that CD40 ligation leads to "reticulation" of DC, promoting intercellular transfer between DC with consecutive improved antigen-presenting capacity. 39 Therefore, our approach was to mimic CD40-CD40L interaction by CD40L-transfected 3T3 cells and thus establish an in vitro method to quantify the TH1-polarizing capacity of in vitro generated DC by IL-12 production after CD40-ligation.
In this study, we show that -in contrast to DC from healthy individuals-interferons are not sufficiently able to increase the TH1-polarizing capacity of DC from CML patients as compared to our maturation protocol including TNF-α alone. Since phenotype and cytokine profiles of DC have been extensively characterized 40 , our study focused on IL-12-and IL-10-production, which is assumed to reflect the ability of in vitro generated DC to induce TH1
polarization. Therefore, we used IL-12/IL-10 ratios as a measure for the TH1-polarizing capacity of DC. 32 Essentially we asked whether IL-12 production can be increased by IFN-α and/or IFN-γ in DC from CML patients in chronic phase. Our results with DC from healthy donors generated in the presence of IFN-γ confirm that IL-12 production can be increased by IFN-γ after CD40 ligation, however, this effect was not observed with DC from chronic phase Increased cell adherence has previously been described to impair DC maturation and cytokine secretion. 32 However, in our case this would neither explain the difference between healthy donors and CML patients nor the substantial reduction of the DC yield that was observed after inclusion of interferons into the maturation cocktail. Therefore, it has to be assumed that -besides inducing a higher cell adherence -interferons also reduce the percentage of surviving cells during DC culture. While increased cell adherence was a common feature both in DC from healthy donors and from CML patients, the lack of IL-12 production upon maturation in the presence of interferons was only found in DC from CML patients and thus seems to be CML-related. CML-related features leading to this difference might be: 1) direct cytotoxic effects of interferons on "leukemic" (= BCR/ABL+) PBMC and/or "leukemic" DC. This seems at least very likely since interferons were the standard of care for a long period; [41] [42] [43] [44] 2) an impairment of DC function itself which has been previously reported; In conclusion, our results are in line with previous publications showing that functional DC can be generated ex vivo in CML patients, both in the chronic phase of the disease (giving rise to BCR/ABL+ "leukemic" DC) and in cytogenetic/molecular remission. 15, 26, [47] [48] [49] With regard to an interferon-induced "DC1 phenotype" that has been previously described (reviewed in 40 ), we could confirm higher IL-12 secretion in DC from healthy donors as compared to our standard cocktail containing GM-CSF, IL-4 and TNF-α alone. However, this interferon-induced increase in IL-12 production could not be found in DC from CML patients.
Due to higher cell adherence and a lower DC yield observed after the use of interferons, we currently do not recommend their use under the culture conditions used in our GMP facility.
Immunotherapeutic perspectives in CML in the MRD setting under TKI therapy include vaccination strategies with DC + additional immune checkpoint inhibitors. Consequently, improved large-scale DC generation from CML patients is clearly needed. Therefore, refined protocols for DC generation, which address the challenges of cell adherence/ cell yield and -at the same time -support an appropriate DC1-phenotype, are warranted.
Material and Methods

Generation of DC from PBMCs
DC were generated from eight healthy donors and three patients with chronic phase BCR/ABL+ CML as previously described and in accordance with local ethical guidelines. were harvested and washed three times and were then frozen and stored on liquid nitrogen as previously described. 16 The phenotype of DC was characterized by flow cytometry as previously described. 15 The purity of the DC culture was always > 70%, T cell contamination was <10%.
Proliferation assays
Proliferation assays were performed as previously described. CBA were performed as previously described. 50 Briefly, 
